ReviewClinical ophthalmology (Auckland, N.Z.)2025
Understanding Keratoconus in Down Syndrome: From Etiology to Management - A Narrative Review.
Review in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paediatricians are often the first to identify children with DS and their awareness on associated ocular comorbidities, play a critical role in ensuring timely referral to general ophthalmologists for diagnosis and management. Among these, keratoconus (KC) has a significantly higher prevalence among Down syndrome (DS) compared to the general population. The awareness and understanding of KC, is essential for preventing vision loss. This review summarizes the current understanding of KC in DS, on epidemiology, pathophysiology, diagnostic challenges, and management. The children with DS, have thinner and steeper corneas since birth, complicates the diagnostic and management protocols. Poor cooperation of the children for imaging, compromised scan qualities, need for sedation and repeatability of scans poses diagnostic challenges. Early intervention with corneal cross-linking (CXL) is shown to be effective in halting disease progression. The surgical options in advanced cases, carry higher risks in DS patients due to factors such as eye rubbing, increased infection rates, and challenges in postoperative compliance. Managing KC in DS requires a comprehensive approach involving early referral by Paediatricians, pre-emptive diagnosis, and timely intervention with CXL to prevent disease progression. Future research should focus on preclinical gene prediction and developing standardized screening protocols for KC among DS to prevent vision loss and thereby improve quality of life among them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.